These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 32248449)

  • 1. Prognostic Role of Matrix Metalloproteinases 2, 7, 8, 9 and Their Type 1 Tissue Inhibitor in Blood Serum of Patients with Kidney Cancer.
    Kushlinskii NE; Gershtein ES; Alferov AA; Bezhanova SD; Mushtenko VV; Pushkar DY; Matveev VB; Stilidi IS
    Bull Exp Biol Med; 2020 Mar; 168(5):673-676. PubMed ID: 32248449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Significance of Matrix Metalloproteinases in Blood Plasma of Patients with Gastric Cancer.
    Kushlinskii NE; Gershtein ES; Ivannikov AA; Davydov MM; Chang VL; Ognerubov NA; Stilidi IS
    Bull Exp Biol Med; 2019 Jan; 166(3):373-376. PubMed ID: 30627896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneous up-regulation of matrix metalloproteinases 1, 2, 3, 7, 8, 9 and tissue inhibitors of metalloproteinases 1, 4 in serum of patients with chronic obstructive pulmonary disease.
    Navratilova Z; Zatloukal J; Kriegova E; Kolek V; Petrek M
    Respirology; 2012 Aug; 17(6):1006-12. PubMed ID: 22591289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Matrix-metalloproteinases and their inhibitors in plasma and tumor tissue of patients with renal cell carcinoma.
    Lein M; Jung K; Laube C; Hübner T; Winkelmann B; Stephan C; Hauptmann S; Rudolph B; Schnorr D; Loening SA
    Int J Cancer; 2000 Mar; 85(6):801-4. PubMed ID: 10709099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
    Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
    Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer.
    Oberg A; Höyhtyä M; Tavelin B; Stenling R; Lindmark G
    Anticancer Res; 2000; 20(2B):1085-91. PubMed ID: 10810401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Matrix metalloproteinases 2, 7, 9 and tissue inhibitor of matrix metalloproteinase-1 in the sera of patients with bone tumors.
    Kushlinsky NE; Solovyov YN; Babkina IV; Gershtein ES; Bulicheva IV
    Bull Exp Biol Med; 2010 Aug; 149(2):233-5. PubMed ID: 21113498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Matrix metalloproteinases 2, 7, and 9 and tissue inhibitor of metalloproteinases-1 in tumors and serum of patients with ovarian neoplasms.
    Gershtein ES; Levkina NV; Digayeva MA; Laktionov KP; Tereshkina IV; Kushlinsky NE
    Bull Exp Biol Med; 2010 Oct; 149(5):628-31. PubMed ID: 21165404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced systemic matrix metalloproteinase response in Helicobacter pylori gastritis.
    Rautelin HI; Oksanen AM; Veijola LI; Sipponen PI; Tervahartiala TI; Sorsa TA; Lauhio A
    Ann Med; 2009; 41(3):208-15. PubMed ID: 18979291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of circulating matrix metalloproteinase-9 to tissue inhibitor of metalloproteinases-2 ratio as a predictor of disease progression in patients with metastatic renal cell carcinoma receiving sunitinib.
    Miyake H; Nishikawa M; Tei H; Furukawa J; Harada K; Fujisawa M
    Urol Oncol; 2014 Jul; 32(5):584-8. PubMed ID: 24680659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Matrix Metalloproteinases and Their Tissue Inhibitors in Blood Serum of Patients with Endometrial Cancer: Clinical and Morphological Correlations.
    Gershtein ES; Mushtenko SV; Ermilova VD; Levchenko NE; Kushlinskii NE
    Bull Exp Biol Med; 2018 May; 165(1):75-79. PubMed ID: 29796809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic role of tumor-associated proteases in colorectal cancer.
    Kushlinskii NE; Gershtein ES; Korotkova EA; Prorokov VV
    Bull Exp Biol Med; 2013 Jan; 154(3):365-9. PubMed ID: 23484202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preoperative levels of matrix metalloproteinase-7 and -9 and tissue inhibitor of matrix metalloproteinase-1 relation to pathologic parameters in bladder carcinoma patients.
    Gunes M; Kemik AS; Pirincci N; Gecit I; Taken K; Yuksel MB; Kaba M; Eryilmaz R
    Asian Pac J Cancer Prev; 2013; 14(2):873-6. PubMed ID: 23621254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis.
    Niebroj-Dobosz I; Janik P; Sokołowska B; Kwiecinski H
    Eur J Neurol; 2010 Feb; 17(2):226-31. PubMed ID: 19796283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The matrix metalloproteinase-7 and pro-enzyme of metalloproteinase-1 as a potential marker for patients with rectal cancer without distant metastasis.
    Fuksiewicz M; Kotowicz B; Rutkowski A; Kowalska M
    Tumour Biol; 2015 May; 36(5):3629-35. PubMed ID: 25549795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Profile of Circulating Matrix Metalloproteinases in Patients Undergoing Lower Limb Endovascular Interventions for Peripheral Arterial Disease.
    Giagtzidis IT; Kadoglou NP; Mantas G; Spathis A; Papazoglou KO; Karakitsos P; Liapis CD; Karkos CD
    Ann Vasc Surg; 2017 Aug; 43():188-196. PubMed ID: 28288884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum MMP-8 and TIMP-1 as prognostic biomarkers in gastric cancer.
    Laitinen A; Hagström J; Mustonen H; Kokkola A; Tervahartiala T; Sorsa T; Böckelman C; Haglund C
    Tumour Biol; 2018 Sep; 40(9):1010428318799266. PubMed ID: 30192205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor marker potential of serum matrix metalloproteinases in patients with head and neck cancer.
    Kuropkat C; Plehn S; Herz U; Dünne AA; Renz H; Werner JA
    Anticancer Res; 2002; 22(4):2221-7. PubMed ID: 12174907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tissue MMP-2 and MMP-9 [corrected] are better prognostic factors than serum MMP-2/TIMP-2--complex or TIMP-1 [corrected] in stage [corrected] I-III lung carcinoma.
    Hoikkala S; Pääkkö P; Soini Y; Mäkitaro R; Kinnula V; Turpeenniemi-Hujanen T
    Cancer Lett; 2006 May; 236(1):125-32. PubMed ID: 15982804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significant relationship of matrix metalloproteinase 9 with nuclear grade and prognostic impact of tissue inhibitor of metalloproteinase 2 for incidental clear cell renal cell carcinoma.
    Kawata N; Nagane Y; Hirakata H; Ichinose T; Okada Y; Yamaguchi K; Takahashi S
    Urology; 2007 Jun; 69(6):1049-53. PubMed ID: 17572184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.